These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31608328)

  • 1. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory.
    Rivera-Molina Y; Jiang H; Fueyo J; Nguyen T; Shin DH; Youssef G; Fan X; Gumin J; Alonso MM; Phadnis S; Lang FF; Gomez-Manzano C
    Neurooncol Adv; 2019; 1(1):vdz009. PubMed ID: 31608328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
    Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
    PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
    Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
    Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
    Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.
    Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Cherepanov SA; Yusubalieva GM; Ruzsics Z; Lipatova AV; Chekhonin VP
    Mol Ther Oncolytics; 2022 Mar; 24():230-248. PubMed ID: 35071746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death.
    Alonso MM; Jiang H; Yokoyama T; Xu J; Bekele NB; Lang FF; Kondo S; Gomez-Manzano C; Fueyo J
    Mol Ther; 2008 Mar; 16(3):487-93. PubMed ID: 18253154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
    Fueyo J; Alemany R; Gomez-Manzano C; Fuller GN; Khan A; Conrad CA; Liu TJ; Jiang H; Lemoine MG; Suzuki K; Sawaya R; Curiel DT; Yung WK; Lang FF
    J Natl Cancer Inst; 2003 May; 95(9):652-60. PubMed ID: 12734316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
    Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM
    Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Jiang H; Shin DH; Nguyen TT; Fueyo J; Fan X; Henry V; Carrillo CC; Yi Y; Alonso MM; Collier TL; Yuan Y; Lang FF; Gomez-Manzano C
    Clin Cancer Res; 2019 Nov; 25(22):6801-6814. PubMed ID: 31455679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.
    Martinez-Velez N; Marigil M; García-Moure M; Gonzalez-Huarriz M; Aristu JJ; Ramos-García LI; Tejada S; Díez-Valle R; Patiño-García A; Becher OJ; Gomez-Manzano C; Fueyo J; Alonso MM
    Acta Neuropathol Commun; 2019 Apr; 7(1):64. PubMed ID: 31036068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.
    González-Morales A; Zabaleta A; García-Moure M; Alonso MM; Fernández-Irigoyen J; Santamaría E
    J Proteomics; 2019 Mar; 194():168-178. PubMed ID: 30503830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
    Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
    Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
    Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM
    Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
    Cockle JV; Rajani K; Zaidi S; Kottke T; Thompson J; Diaz RM; Shim K; Peterson T; Parney IF; Short S; Selby P; Ilett E; Melcher A; Vile R
    Neuro Oncol; 2016 Apr; 18(4):518-27. PubMed ID: 26409567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
    Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
    Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.